PT Indofarma Tbk (ISX:INAF) EBIT : Rp-492,894 Mil (TTM As of Sep. 2023)

View and export this data going back to 2001. Start your Free Trial

What is PT Indofarma Tbk EBIT?

PT Indofarma Tbk's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2023 was Rp-67,048 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2023 was Rp-492,894 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. PT Indofarma Tbk's annualized ROC % for the quarter that ended in Sep. 2023 was -19.54%. PT Indofarma Tbk's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -59.21%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. PT Indofarma Tbk's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -49.24%.

PT Indofarma Tbk EBIT Historical Data

The historical data trend for PT Indofarma Tbk's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PT Indofarma Tbk EBIT Chart

PT Indofarma Tbk Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT

Get a 7-Day Free Trial

22,580.33

46,503.03

56,335.78

51,729.94

-479,476.87

PT Indofarma Tbk Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EBIT	Get a 7-Day Free Trial															-85,780.18	-319,362.11	-51,904.49	-54,579.83	-67,047.70

Competitive Comparison of PT Indofarma Tbk's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, PT Indofarma Tbk's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PT Indofarma Tbk's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PT Indofarma Tbk's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where PT Indofarma Tbk's EV-to-EBIT falls into.

PT Indofarma Tbk EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp-492,894 Mil.

PT Indofarma Tbk (ISX:INAF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

PT Indofarma Tbk's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

	ROC % (Q: Sep. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Sep. 2023 ))	/ count )
=	-253355.94 * ( 1 - 13.32% )	/	( (1118614.799	+	1129435.118)	/ 2 )
=	-219608.928792	/	1124024.9585
=	-19.54 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1559064.75	-	701880.935	-	( 297164.172	-	max(0, 1151004.523	-	889573.539	+	297164.172	))
=	1118614.799

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1491062.01	-	701116.704	-	( 244807.114	-	max(0, 1156470.213	-	816980.401	+	244807.114	))
=	1129435.118

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

PT Indofarma Tbk's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Sep. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-268190.812	/	( ( (454787.851 + max(-241460.358, 0))	+	(451125.521 + max(-262966.866, 0)) )	/	2 )
=	-268190.812	/	( ( 454787.851	+	451125.521 )	/	2 )
=	-268190.812	/	452956.686
=	-59.21 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(162774.696	+	257028.248	+	138264.223)	-	(701880.935	+	0	+	97646.59)
=	-241460.358

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(146211.432	+	243092.017	+	148337.368)	-	(701116.704	+	0	+	99490.979)
=	-262966.866

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

PT Indofarma Tbk's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2023 )
	=	-492894.134	/	1001105.171
	=	-49.24 %

PT Indofarma Tbk EBIT Related Terms

Thank you for viewing the detailed overview of PT Indofarma Tbk's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

PT Indofarma Tbk (ISX:INAF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PT Indofarma Tbk (ISX:INAF) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Jalan Indofarma No. 1, Cikarang Barat, Jawa Bara, Bekasi, IDN, 17530

Website

http://www.indofarma.id

PT Indofarma Tbk is a specialty and generic drug manufacturing company. The company has four business segments - Medicine, Medical Devices and others, Pharmaceutical Engineering, and Aliansi Strategis Segment. The Medicine business segment includes drug production, marketing and distribution and sales. The Medical Device Segment includes medical devices and other products. The Pharmaceutical Engineering Segment includes the sale and maintenance of packaging machines for the pharmaceutical industry to external parties.

PT Indofarma Tbk (ISX:INAF) Headlines

No Headlines